Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
New findings from a citizen science study suggest that microdosing psychedelics could be a valuable tool in the battle against poor mental health.
Leaders in the fields of psychedelics and cannabis will join together for the GCI Virtual Summit.
In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.
A group of experts gathered to discuss microdosing, and separate the fact from the fiction on the safety and efficacy of the practice.
Awakn has signed a Memorandum of Understanding (MOU) with the Devon Partnership NHS Trust and the University of Exeter to increase access to psychedelic-assisted therapy for...
The non-profit Mind Medicine Australia will be hosting the summit that will bring together leaders in the field of psychedelics to discuss the benefits of the...
Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.
A study undertaken over a five-year period has shown that a single dose of ketamine improved thinking and reasoning in people who had expressed thoughts of...
A small study has reported that two doses of psilocybin received with supportive psychotherapy relieves depression.